IL1B and chronic obstructive pulmonary disease: However, we found that treatment with AZD0530 at a dosage of 5 mg/kg did not ameliorate inflammatory cells, neutrophils, or IL-1β levels, indicating a dose-dependent anti-COPD effect of AZD0530.